-
卵巢癌是女性生殖系统中较为常见的一种恶性肿瘤,其发病率仅次于宫颈癌、子宫体癌,此病具有疾病隐匿、早期症状不明显的特点,且目前临床上对于卵巢癌无特异性的诊断指标,大多数病人在疾病诊断时已经处于晚期,错过了最佳的治疗时机,病人预后较差,病死率较高[1]。因此寻找有效的诊断卵巢癌的敏感指标,对病人的早期诊断及治疗具有重要的意义。有研究[2]采用人附睾蛋白4(HE4)、糖类抗原125(CA125)、人溶血磷脂酸(LPA)对上皮性卵巢癌病人进行联合诊断,其研究结果中认为HE4在卵巢癌组织中高表达,与卵巢癌细胞所分泌的LPA升高共同参与此病的发生。亦有研究[3]认为,HE4与糖类抗原199(CA199)相关,共同参与卵巢癌的发生,可作为卵巢癌的早期诊断指标。另外有研究[4]发现,LPA、CA199与上皮性卵巢癌病人治疗效果相关,可作为病人病情诊断指标。基于上述研究,本文旨在探讨HE4、CA199及LPA在卵巢癌中的表达及与临床病理特征的相关性,以期为临床上卵巢癌的早期诊治提供参考。
-
血清HE4、CA199、血浆LPA水平,卵巢癌组血清均高于卵巢良性病变组和健康对照组,卵巢良性病变组均高于健康对照组(P < 0.05)(见表 1)。
分组 n HE4/(pmol/mL) CA199/(U/mL) LPA/(μmol/L) 健康对照组 100 44.23±5.46 13.12±1.13 2.03±0.24 卵巢良性病变组 120 59.68±10.24* 16.24±3.46* 2.29±0.98* 卵巢癌组 140 316.25±49.68*# 134.25±46.58*# 5.16±1.12*# F — 2 966.33 718.87 465.51 P — < 0.01 < 0.01 < 0.01 MS组内 — 1 004.189 849.128 0.825 q检验:与健康对照组比较*P < 0.05;与卵巢良性病变组比较#P < 0.05 表 1 3组研究对象血清HE4、CA199、血浆LPA水平的比较(x±s)
-
HE4、CA199、LPA在卵巢癌组卵巢组织中的阳性表达率均显著高于卵巢良性病变组(P < 0.01)(见表 2、图 1~3)。
分组 n HE4 CA199 LPA 卵巢良性病变组 120 32(26.67) 28(23.33) 42(35.00) 卵巢癌组 140 129(92.14) 131(93.57) 118(84.29) χ2 — 117.49 134.19 66.31 P — < 0.01 < 0.01 < 0.01 表 2 HE4、CA199、LPA在卵巢良性病变组与卵巢癌组卵巢组织中的阳性表达情况比较[n;百分率(%)]
-
HE4、CA199、LPA表达与卵巢癌病人病理类型、肿瘤直径无相关性(P>0.05),与卵巢癌病人临床分期、分化程度、有无淋巴结转移有相关性(P < 0.01);其中临床分期Ⅲ~Ⅳ期、低分化程度、有淋巴结转移的卵巢癌病人HE4、CA199、LPA表达较高(见表 3)。
指标 n HE4/(pmol/mL) CA199/(U/mL) LPA/(μmol/L) 临床分期 Ⅰ~Ⅱ期 36 246.38±68.59 48.62±9.65 3.46±0.24 Ⅲ~Ⅳ期 104 459.68±124.25 124.26±32.15 5.16±1.02 t — 9.78 13.87 9.88 P — < 0.01 < 0.01 < 0.01 分化程度 高 41 182.46±24.15 76.35±12.04 3.10±0.10 中 46 235.56±50.69△ 110.23±45.23△ 3.21±0.23△ 低 53 462.25±126.35△▲ 134.25±68.59△▲ 5.63±1.10△▲ F — 151.825 15.51 210.09 P — < 0.01 < 0.01 < 0.01 MS组内 — 7 073.723 2 499.970 0.480 病理类型 浆液性 76 245.26±42.25 124.25±35.26 4.13±0.65 非浆液性 64 252.25±43.26 125.26±35.49 4.16±0.68 t — 0.96 0.17 0.27 P — >0.05 >0.05 >0.05 淋巴结转移 有 62 398.56±102.12 135.49±58.25 5.86±1.10 无 78 265.35±53.27 109.58±23.58 3.45±0.24 t — 9.95 3.58 18.81 P — < 0.01 < 0.01 < 0.01 肿瘤直径/cm ≥5 59 232.16±68.59 124.25±15.36 4.10±0.21 < 5 81 231.25±72.16 126.35±16.69 4.13±0.20 t — 0.08 0.76 0.86 P — >0.05 >0.05 >0.05 q检验:与高分化相比较△P < 0.05;与中分化相比较▲P < 0.05 表 3 HE4、CA199、LPA水平与卵巢癌病人临床病理特征的相关性分析(x±s)
-
HE4、CA199、LPA之间进行Pearson相关性分析,HE4与CA199呈现显著正相关关系(r=0.183, P < 0.05),HE4与LPA呈显著正相关关系(r=0.216, P < 0.05),CA199与LPA之间呈正相关(r=0.209, P < 0.05)。
人附睾蛋白4、CA199、LPA在卵巢癌中的表达及与临床病理特征的相关性
Expression of human epididymal protein 4, CA199 and LPA in ovarian cancer, and its correlation with clinicopathological features
-
摘要:
目的探究人附睾蛋白4(HE4)、糖类抗原199(CA199)、人溶血磷脂酸(LPA)在卵巢癌中的表达及与临床病理特征的相关性。 方法选择卵巢癌病人140例作为卵巢癌组,同期选取因卵巢良性病变而行手术切除的病人120例作为卵巢良性病变组,并择同期行健康体检女性100名作为健康对照组。检测3组研究对象HE4、CA199、LPA水平,比较HE4、CA199、LPA在卵巢良性病变组与卵巢癌组卵巢组织中的阳性表达情况,分析HE4、CA199、LPA与卵巢癌病人临床病理特征的相关性,HE4、CA199、LPA之间的相关性。 结果血清HE4、CA199、血浆LPA水平,卵巢癌组血清均高于卵巢良性病变组和健康对照组,卵巢良性病变组均高于健康对照组(P < 0.05);HE4、CA199、LPA在卵巢癌组卵巢组织中的阳性表达率均高于卵巢良性病变组(P < 0.01)。HE4、CA199、LPA表达与卵巢癌病人病理类型、肿瘤直径无相关性(P>0.05);与卵巢癌病人临床分期、分化程度、有无淋巴结转移有相关性(P < 0.01),其中临床分期Ⅲ~Ⅳ期、低分化程度、有淋巴结转移的病人HE4、CA199、LPA表达水平较高。HE4与CA199之间呈正相关(r=0.183, P < 0.05),HE4与LPA之间呈正相关(r=0.216, P < 0.05),CA199与LPA之间呈正相关(r=0.209, P < 0.05)。 结论HE4、CA199、LPA在卵巢癌病人中为高表达,且与病人临床分期、分化程度、有无淋巴结转移相关。 Abstract:ObjectiveTo study the correlations among the expression levels of human epididymal protein 4(HE4), carbohydrate antigen 199(CA199) and human lysophosphatidic acid(LPA) in ovarian cancer, and its clinicopathological features. MethodsOne hundred and forty patients with ovarian cancer, 120 ovarian benign lesions patients treated with operation and 100 healthy women were divided into the ovarian cancer group, ovarian benign lesion group and healthy control group, respectively.The expression levels of HE4, CA199 and LPA in three groups were detected, the positive expression of HE4, CA199 and LPA between ovarian benign lesion group and ovarian cancer group were compared.The correlation of the HE4, CA199 and LPA with clinicopathological characteristics of ovarian cancer patients, and correlation among the expression of HE4, CA199 and LPA were analyzed. ResultsThe serum levels of HE4, CA199 and plasma LPA in ovarian cancer group were higher than those in benign ovarian lesion group and healthy control group(P < 0.05), and the positive rates of HE4, CA199 and LPA in ovarian cancer group were higher than those in benign ovarian lesion group(P < 0.01).The expression levels of HE4, CA199 and LPA were not correlated with the pathological type and diameter of ovarian cancer(P>0.05), but which were related to the clinical stage, differentiation degree and lymph node metastasis of ovarian cancer patients(P < 0.01).The expression levels of HE4, CA199 and LPA in patients with stage Ⅲ-Ⅳ, low differentiation and lymph node metastasis were higher.The HE4 level was positively correlated with CA199(r=0.183, P < 0.05), the HE4 level was positively correlated with LPA(r=0.216, P < 0.05), and the CA199 level was positively correlated with LPA(r=0.209, P < 0.05). ConclusionsThe expression levels of HE4, CA199 and LPA in ovarian cancer patients are high, which are related to the clinical stage, differentiation degree and lymph node metastasis. -
表 1 3组研究对象血清HE4、CA199、血浆LPA水平的比较(x±s)
分组 n HE4/(pmol/mL) CA199/(U/mL) LPA/(μmol/L) 健康对照组 100 44.23±5.46 13.12±1.13 2.03±0.24 卵巢良性病变组 120 59.68±10.24* 16.24±3.46* 2.29±0.98* 卵巢癌组 140 316.25±49.68*# 134.25±46.58*# 5.16±1.12*# F — 2 966.33 718.87 465.51 P — < 0.01 < 0.01 < 0.01 MS组内 — 1 004.189 849.128 0.825 q检验:与健康对照组比较*P < 0.05;与卵巢良性病变组比较#P < 0.05 表 2 HE4、CA199、LPA在卵巢良性病变组与卵巢癌组卵巢组织中的阳性表达情况比较[n;百分率(%)]
分组 n HE4 CA199 LPA 卵巢良性病变组 120 32(26.67) 28(23.33) 42(35.00) 卵巢癌组 140 129(92.14) 131(93.57) 118(84.29) χ2 — 117.49 134.19 66.31 P — < 0.01 < 0.01 < 0.01 表 3 HE4、CA199、LPA水平与卵巢癌病人临床病理特征的相关性分析(x±s)
指标 n HE4/(pmol/mL) CA199/(U/mL) LPA/(μmol/L) 临床分期 Ⅰ~Ⅱ期 36 246.38±68.59 48.62±9.65 3.46±0.24 Ⅲ~Ⅳ期 104 459.68±124.25 124.26±32.15 5.16±1.02 t — 9.78 13.87 9.88 P — < 0.01 < 0.01 < 0.01 分化程度 高 41 182.46±24.15 76.35±12.04 3.10±0.10 中 46 235.56±50.69△ 110.23±45.23△ 3.21±0.23△ 低 53 462.25±126.35△▲ 134.25±68.59△▲ 5.63±1.10△▲ F — 151.825 15.51 210.09 P — < 0.01 < 0.01 < 0.01 MS组内 — 7 073.723 2 499.970 0.480 病理类型 浆液性 76 245.26±42.25 124.25±35.26 4.13±0.65 非浆液性 64 252.25±43.26 125.26±35.49 4.16±0.68 t — 0.96 0.17 0.27 P — >0.05 >0.05 >0.05 淋巴结转移 有 62 398.56±102.12 135.49±58.25 5.86±1.10 无 78 265.35±53.27 109.58±23.58 3.45±0.24 t — 9.95 3.58 18.81 P — < 0.01 < 0.01 < 0.01 肿瘤直径/cm ≥5 59 232.16±68.59 124.25±15.36 4.10±0.21 < 5 81 231.25±72.16 126.35±16.69 4.13±0.20 t — 0.08 0.76 0.86 P — >0.05 >0.05 >0.05 q检验:与高分化相比较△P < 0.05;与中分化相比较▲P < 0.05 -
[1] 蒋绍艳, 常宏, 樊丹怡, 等. 淫羊藿苷对人卵巢癌细胞株的肿瘤恶性行为的抑制作用研究[J]. 四川大学学报(医学版), 2018, 49(4): 530. [2] 沈慧敏, 梁武凤, 杨君, 等. 人附睾蛋白4、溶血磷脂酸和糖类抗原125联合检测在上皮性卵巢癌诊断中的价值[J]. 新乡医学院学报, 2014, 31(11): 922. [3] 郑红云, 于奇, 申复进, 等. 血清HE4、CA125和CA199联合检测对卵巢癌早期诊断的临床研究[J]. 国际检验医学杂志, 2017, 38(19): 2680. doi: 10.3969/j.issn.1673-4130.2017.19.009 [4] 王婉, 胡倩倩, 杨文静, 等. 多西他赛联合奈达铂对上皮性卵巢癌患者血清LPA、CA199、CEA、白细胞介素及免疫功能的影响[J]. 海南医学院学报, 2016, 22(20): 2478. [5] 黄汉陵, 徐航, 向安琳. HE4、AFP、CA125和CEA在卵巢癌中的诊断意义[J]. 中国免疫学杂志, 2018, 34(11): 1712. doi: 10.3969/j.issn.1000-484X.2018.11.023 [6] 郭润梅, 杜蓉, 王丹, 等. 血清HE4、CA125浓度水平在预测上皮性卵巢癌预后中的价值[J]. 临床检验杂志, 2019, 37(2): 117. [7] 石慧, 胡建国. HE4、CA125联合D-二聚体检测对卵巢癌的诊断价值[J]. 蚌埠医学院学报, 2020, 45(4): 523. [8] KARACAN T, OZYUREK E, YESIRALIOGLU S, et al. Endometriomas with low-risk malignancy potential in ultrasonography with high human epididymis protein 4 and risk of ovarian malignancy algorithm: a cases series[J]. Gynecol Endocrinol, 2020, 36(2): 117. doi: 10.1080/09513590.2019.1653842 [9] 贺帅, 马黎明, 来艳君. HE4、CA125、SMRP检测联合ROMA在卵巢癌诊断中的应用[J]. 实用癌症杂志, 2019, 34(3): 362. doi: 10.3969/j.issn.1001-5930.2019.03.004 [10] 马书丽, 李静, 袁媛, 等. 卵巢上皮癌患者CA125和HE4水平及其临床意义分析[J]. 国际检验医学杂志, 2019, 40(14): 1759. doi: 10.3969/j.issn.1673-4130.2019.14.023 [11] GUO J, YU J, SONG X, et al. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: a meta-analysis[J]. Open Med(Wars), 2017, 12: 131. doi: 10.1515/med-2017-0020 [12] 李炜, 智明春, 李贞爱, 等. CA125、CA199、CEA联合彩色多普勒超声诊断卵巢癌的临床价值[J]. 解放军预防医学杂志, 2018, 36(10): 1312. [13] 李丹妍, 王銮虹, 邱小华, 等. 血清CA125、CA199、AFP和CEA联合检测在卵巢癌诊断中的临床价值[J]. 中国妇幼保健, 2018, 33(8): 1731. [14] 林莉, 王金华. 肿瘤相关因子在卵巢癌中的表达及其与淋巴结转移相关性研究[J]. 中国临床药理学杂志, 2015, 31(22): 2211. [15] JESIONOWSKA A, CECERSKA-HERYC E, MATOSZKA N, et al. Lysophosphatidic acid signaling in ovarian cancer[J]. J Recept Signal Transduct Res, 2015, 35(6): 578. doi: 10.3109/10799893.2015.1026444 [16] 吴瑜霞, 杨秀华, 曾瑞兰, 等. LPA对比CA125在卵巢癌不同临床分期中表达水平分析[J]. 热带医学杂志, 2015, 15(6): 760. [17] SEO EJ, KWON YW, JANG IH, et al. Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism[J]. Stem Cells, 2016, 34(3): 551. doi: 10.1002/stem.2279 [18] MINIS E, HOLCOMB K, SISTI G, et al. Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: a pilot study[J]. Eur J Obstet Gynecol Reprod Biol X, 2019, 2: 100012. doi: 10.1016/j.eurox.2019.100012 [19] JEONG KJ, PARK SY, CHO KH, et al. Correction: The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion[J]. Oncogene, 2019, 38(25): 5108. doi: 10.1038/s41388-019-0769-7